CA3084246A1 - Hla class i-restricted t cell receptors against mutated ras - Google Patents

Hla class i-restricted t cell receptors against mutated ras Download PDF

Info

Publication number
CA3084246A1
CA3084246A1 CA3084246A CA3084246A CA3084246A1 CA 3084246 A1 CA3084246 A1 CA 3084246A1 CA 3084246 A CA3084246 A CA 3084246A CA 3084246 A CA3084246 A CA 3084246A CA 3084246 A1 CA3084246 A1 CA 3084246A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
tcr
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3084246A
Other languages
English (en)
French (fr)
Inventor
Rami Youseph
Yong-Chen LU
Gal CAFRI
Steven A. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA3084246A1 publication Critical patent/CA3084246A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
CA3084246A 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras Pending CA3084246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594244P 2017-12-04 2017-12-04
US62/594,244 2017-12-04
PCT/US2018/063581 WO2019112941A1 (en) 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras

Publications (1)

Publication Number Publication Date
CA3084246A1 true CA3084246A1 (en) 2019-06-13

Family

ID=64949411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084246A Pending CA3084246A1 (en) 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras

Country Status (15)

Country Link
US (2) US11466071B2 (OSRAM)
EP (1) EP3720478A1 (OSRAM)
JP (3) JP7385566B2 (OSRAM)
KR (1) KR20200115484A (OSRAM)
CN (2) CN119162251A (OSRAM)
AU (2) AU2018378200B2 (OSRAM)
BR (1) BR112020011111A2 (OSRAM)
CA (1) CA3084246A1 (OSRAM)
CR (1) CR20200287A (OSRAM)
EA (1) EA202091335A1 (OSRAM)
IL (1) IL275031A (OSRAM)
MA (2) MA51043A (OSRAM)
MX (1) MX2020005765A (OSRAM)
SG (1) SG11202005236QA (OSRAM)
WO (1) WO2019112941A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
CA3127673A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
EP3760217A1 (en) 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CU20220044A7 (es) * 2020-02-12 2023-06-13 Us Health Receptor de células t restringido por hla de la clase i contra ras con mutación g12d
BR112022015897A2 (pt) * 2020-02-14 2022-10-18 Us Health Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
AU2021225872A1 (en) * 2020-02-26 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12V mutation
CA3185483A1 (en) * 2020-07-16 2022-01-20 Noam LEVIN Hla class ii-restricted drb t cell receptors against ras with g12v mutation
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
KR102488353B1 (ko) * 2020-10-08 2023-01-12 부산대학교 산학협력단 돌연변이 kras를 표적하는 펩타이드 및 이의 용도
AU2021389909A1 (en) * 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
AU2022283277A1 (en) * 2021-05-25 2023-12-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
EP4466283A1 (en) 2022-01-21 2024-11-27 T-Knife GmbH Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117430689A (zh) * 2022-11-04 2024-01-23 新景智源生物科技(苏州)有限公司 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
IL327158A (en) * 2023-09-15 2026-05-01 Funda??O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud T-type receptor against mKRAS7-16 G12V and G12C
IL327155A (en) * 2023-09-15 2026-05-01 Funda??O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud T-receptor variant against mKRAS7-16 G12V
WO2025125590A2 (en) * 2023-12-15 2025-06-19 Genovie Ab Tcr recognizing g12v mutated ras and uses thereof
EP4570263A1 (en) * 2023-12-15 2025-06-18 Genovie AB Tcrs recognizing g12v mutated ras and uses thereof
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation
CN119350472B (zh) * 2024-12-25 2025-04-04 北京可瑞生物科技有限公司 修饰的靶向kras g12v的t细胞受体或其片段以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CN103124740B (zh) * 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
BR112018012694A2 (pt) * 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh composição de célula dendrítica, vacina de célula dendrítica, composição e kit
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US12221627B2 (en) * 2017-12-04 2025-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

Also Published As

Publication number Publication date
JP2023175703A (ja) 2023-12-12
SG11202005236QA (en) 2020-07-29
JP2021505136A (ja) 2021-02-18
EA202091335A1 (ru) 2020-10-15
MA51042A (fr) 2020-10-14
MA51043A (fr) 2020-10-14
AU2018378200B2 (en) 2025-02-27
JP7385566B2 (ja) 2023-11-22
WO2019112941A1 (en) 2019-06-13
US20230026180A1 (en) 2023-01-26
JP7620676B2 (ja) 2025-01-23
AU2025203455A1 (en) 2025-06-05
BR112020011111A2 (pt) 2020-11-17
US11466071B2 (en) 2022-10-11
KR20200115484A (ko) 2020-10-07
CN119162251A (zh) 2024-12-20
US20210079058A1 (en) 2021-03-18
CN111836638A (zh) 2020-10-27
EP3720478A1 (en) 2020-10-14
AU2025203455A9 (en) 2026-03-12
AU2018378200A1 (en) 2020-07-02
CN111836638B (zh) 2024-10-29
IL275031A (en) 2020-07-30
MX2020005765A (es) 2020-09-25
CR20200287A (es) 2020-11-11
JP2025072378A (ja) 2025-05-09

Similar Documents

Publication Publication Date Title
JP7620676B2 (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20200129555A1 (en) Hla-a3-restricted t cell receptors against mutated ras
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
AU2020211922B2 (en) HLA class II-restricted T cell receptors against RAS with G12R mutation
US12577286B2 (en) T cell receptors which recognize mutated EGFR
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
US20240190940A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
EA045513B1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250313

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250715

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260323